AzTrials
AzTrials

HealthyHFANCT05230836

HFAC Stimulation (30-50 Kilohertz) in Healthy Volunteers (High Frequency Alternating Current Stimulation)

A study testing High-frequency alternating current stimulation in people with Healthy and Nerve Block, run by University of Castilla-La Mancha at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

High-frequency alternating current (HFAC) stimulation (between 1 kilohertz (kHz) and 100 kHz) on the peripheral nerve has been shown in basic animal research to produce a rapidly reversible nerve block without nerve damage. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Healthy, Nerve Block, Pain
What is being tested?
High-frequency alternating current stimulation
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
34 participants
Where
1 siteSpain
Study dates
10 Feb 2022to 25 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy volunteer participants.
  • Ability to perform all clinical tests and understand the study protocol, as well as obtain informed consent.
  • Tolerance to the application of electrotherapy.

Who cannot join

  • Having been treated with an electric current similar to the one applied prior to the intervention.
  • Neurological pathology of peripheral or central origin.
  • Altered sensitivity in the area of application of the intervention.
  • No compromise of continuity.
  • History of neuromuscular disease.
  • Epilepsy.
Show all 15Show fewer
  • Trauma, surgery or pain affecting the upper limb.
  • Diabetes.
  • History of cancer.
  • Cardiovascular, metabolic or immunological diseases.
  • Presence of pacemaker or any other implanted electrical device.
  • Taking medication during the study and in the 7 days prior to the study.
  • Consumption of narcotic substances during the study and in the 7 days prior to the study.
  • Presence of tattoos or any other external agent introduced in the area of treatment and treatment and assessment area (hand).
  • Pregnancy.

Trial locations and contacts

1 site in 1 country.

Juan Fernández-Pérez, PhD student contact

+34691336523

juanjose.fernandez@uclm.es

Juan Avendaño-Coy, PhD contact

926051649 ext. 5814

juan.avendano@uclm.es

Spain1 site, 1 recruiting
  • Castilla-La Mancha University

    Toledo, 45071

    Juan Avendaño-Coy, PhD, 925268800, juan.avendano@uclm.es

    Recruiting

Other trials in Spain

About this study

Official title: Effectiveness and Safety of Electrical Stimulation With Alternating High-frequency Currents (30-50 Kilohertz) on the Sensorimotor System in Healthy Volunteer Subjects

High-frequency alternating current (HFAC) stimulation (between 1 kilohertz (kHz) and 100 kHz) on the peripheral nerve has been shown in basic animal research to produce a rapidly reversible nerve block without nerve damage. In human studies, frequencies between 1 kHz and 30 kHz had been applied (both transcutaneously and percutaneously), showing rapidly reversible sensorimotor changes after stimulation without adverse effects. However, the effect of currents with a frequency higher than 30 kHz, which has been shown to be more effective in eliciting nerve block in primates, has not been investigated in humans.

The main objective of this study is to investigate the safety of the intervention and the effect in healthy volunteers of transcutaneous application of alternating currents with frequencies between 30 kHz and 50 kHz on neurophysiological changes in the nerve (nerve conduction velocity and antidromic sensory action potentials (SNAPs), sensory (pain to pressure, epicritic sensitivity and thermal pain to heat) and motor (maximal isometric force) components of the median nerve.

Read the detailed description

Electrical stimulation with high-frequency alternating currents (between 1 kHz and 100 kHz) on the peripheral nerve has shown, in basic research with animals, that it produces a rapidly reversible nerve block without causing damage to the nerve. In humans, studies have been carried out with frequencies between 1 kHz and 30 kHz applied both transcutaneously and percutaneously, showing rapidly reversible sensorimotor changes after stimulation and without causing adverse effects. However, the effect of currents with a frequency greater than 30 kHz has not been investigated in humans, which has been shown to be more effective in causing nerve block in primates.

The main objective of this study is to investigate the safety of the intervention and the effect in healthy volunteers of the transcutaneous application of alternating currents with frequencies between 30 kHz and 50 kHz on neurophysiological changes in the nerve (nerve conduction velocity and antidromic sensory compound action potentials (PACSA), the sensitive component (pressure pain, epicritic sensitivity and thermal pain to heat) and motor (maximum force) of the median nerve.

A randomized, double-blind, placebo-controlled crossover clinical trial has been designed. The participants will be healthy volunteers between 18 and 40 years old recruited from the students and staff of the Faculty of Physiotherapy and Nursing of the University of Castilla-La Mancha. Four interventions will be performed randomizing the order: Group A: 30 kHz, group B: 40 kHz, group C: 50 kHz and group D: sham electrical stimulation.

Being tested
High-frequency alternating current stimulation, Sham current stimulation
Keywords
high-frequency alternating current stimulation, Nerve block, Pain, Strength, Median nerve
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High-frequency alternating current stimulationOther

    Also called Neuromodest® Cibertec-Inc. CHFS 500i

    For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a "strong but comfortable tingling" sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group

  • Sham current stimulationOther

    Also called Neuromodest® Cibertec-Inc. CHFS 500i sham

    Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold ("strong but comfortable tingling sensation") is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants.

Study groups in NCT05230836
Study groupRoleWhat they receive
30 kilohertzExperimentalAlternating current stimulation at 30 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
Receives: Other: High-frequency alternating current stimulation
40 kilohertzExperimentalAlternating current stimulation at 40 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
Receives: Other: High-frequency alternating current stimulation
50 kilohertzExperimentalAlternating current stimulation at 50 kilohertz via transcutaneous, 15 minutes each intervention with a maximum intensity of 400 milliamperes (mA).
Receives: Other: High-frequency alternating current stimulation
Sham stimulationSham comparatorSham stimulation via transcutaneous, 15 minutes each intervention, following the same procedures as 30, 40 and 50kHz HFAC groups.
Receives: Other: Sham current stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pressure pain threshold

    It will be assessed as an indirect measure of the blockade of the Aδ sensory fibers of the median nerve. Once the applicator is placed perpendicular to the skin, over an uncomfortable spot on the palmar aspect of the non-dominant hand, the pressure shall be increased at a rate of approximately 5 N/s. Three measurements shall be taken with an interval between measurements of 15 seconds, the average of the three measurements shall be taken as the pressure pain threshold.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

Secondary outcomes (7)
  1. Compound antidromic sensitive nerve action potentials

    It will be assessed as a direct measure of blockade of the large diameter sensory fibers Aα and Aβ over the non-dominant hand. Two recording electrodes (model Repusi-Gwc-1.5r reusable conductive ring electromyography electrodes) shall be used and placed on the index finger, the anode over the metacarpophalangeal joint and the cathode over the distal interphalangeal joint. The ground electrode shall be placed over the styloid process of the radius. The location of the median nerve in the forearm is then identified by transcutaneous bipolar stimulation. To evoke the action potential, supramaximal stimuli will be applied using a pulse width of 1000µs at a frequency of 1 Hz. The average of a train of 10 pulses will be collected for subsequent analysis.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

  2. Maximal isometric pinch strength

    It will be assessed as an indirect measure of the blockade of the motor fibers (Aα motor neurons) of the median nerve. Assessment of palmar pincer isometric peak force of the non-dominant hand (distal phalanx of the second and third finger with the distal phalanx of the first finger) shall be performed with a pincer dynamometer (Pinch meter P200 Biometric LTD). Three measurements of the peak isometric pincer force in Kg/f shall be recorded and the average of the three measurements shall be taken as the peak force value. The subject will hold the force for at least 3 seconds and it will be performed progressively until the maximum peak is reached, with at least 15 seconds of recovery between measurements. This measurement has shown excellent validity and reliability for measuring strength in median nerve blocks and neurological pathologies.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

  3. Two points discrimination threshold

    This will be assessed as an indirect measure of the blockage of the Aβ sensory fibers of the median nerve. Two-point tactile discrimination between two points will be carried out on the anterior face of the distal phalanx of the third finger with an esthesiometer (Baseline®). This evaluation will be carried out according to the protocol described by Sang W. et al (2017), instructing the subject to report when they perceive a point or two. The protocol begins with a descending trial with the esthesiometer initially set at a distance of 10 mm and decreasing by 1 mm until the participant reports perceiving a single point. When that happens, several stimuli around that threshold will be given randomly, including stimuli with a single tip. If the subject correctly identifies two of three stimuli while not at a shorter distance, that will be considered their final discrimination threshold.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

  4. Heat pain threshold

    It will be assessed as an indirect measure of the blockade of the type C amyelinic sensory fibers of the median nerve. Hot thermal stimuli will be applied over the thenar eminence in the palmar aspect of the non-dominant hand (dermatome innervated by the median nerve), using a 9 cm2 thermoelectric cell (TSA 2. Medoc, Israel). Three temperature ramp-up measurements will be performed with a time between tests of 30 seconds. The thermal pain threshold to heat shall be determined by the limit method and the mean value of the 3 measurements shall be taken as the threshold value. The starting temperature shall be 32°C and the rate of ascent shall be 1°C/s, with a rate of descent of 8,5°C/s. Subjects shall be instructed to press the device with the contralateral hand when the warm thermal sensation becomes painful and the temperature of the applicator shall automatically decrease. For safety reasons, 50°C shall be set as the cut-off temperature.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

  5. Skin temperature

    A doppler temperature and perfusion monitor (Moor Instruments model DRT4) with a recording sensor placed on the palmar side over the head of the third metacarpal will be used to record skin temperature of the non-dominant hand. An external analog thermometer shall be used to record the ambient temperature.

    Measured: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.

  6. Adverse effects and subjective current sensations

    In order to assess the adverse effects and the subjective perception of the participants, a standardized questionnaire was developed. In this questionnaire, ten items have been established with response options (YES/NO) in relation to heat, cold, sweating, tingling, pain (burning/punching/electrical, superficial/deep), numbness, numbness, stiffness/shrinking, heaviness and/or weakness, together with the area in which they are perceived and an open item in which other effects or sensations that the participant has perceived will be collected. The unpleasantness of the intervention will also be assessed using a 10 cm visual analog scale where 0 corresponds to "not at all unpleasant" and 10 to "as unpleasant as you could receive".

    Measured: Post immediate at 15 minutes and 24 hours after the intervention

  7. Outcome and participant blinding assessment

    Immediately after stimulation intervention (15 min) (30, 40, 50 kHz and sham) the success of blinding will be assessed through five response options: "What type of intervention do you think you have received?" I strongly believe I have received an experimental treatment/ I slightly believe I have received an experimental treatment/ I strongly believe I have received a placebo/ I slightly believe I have received a placebo/ don't know or no answer.

    Measured: Post immediate at 15 minutes each intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2022
  2. Study start10 Feb 2022
  3. Primary completion20 Sep 2022 (estimated)
  4. Study completion25 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Four interventions will be performed in randomized order: Group A: 30 kHz HFAC, group B: 40 kHz HFAC, group C: 50 kHz HFAC and group D: simulated electrical stimulation. kHz (kilohertz)
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
34 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05230836
Sponsor's protocol ID
neuromodest-gifto
Other IDs
2021-006548-28, MCIN/10.13039/501100011033
Acronym
HFA
Status last verified
May 2022
First submitted
14 Jan 2022
Last updated
16 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, figures, images and appendix)

Publications

  • Megia Garcia A, Serrano-Munoz D, Bravo-Esteban E, Ando Lafuente S, Avendano-Coy J, Gomez-Soriano J. [Analgesic effects of transcutaneous electrical nerve stimulation (TENS) in patients with fibromyalgia: A systematic review]. Aten Primaria. 2019 Aug-Sep;51(7):406-415. doi: 10.1016/j.aprim.2018.03.010. Epub 2018 Jul 17. Spanish.

    PubMed 30029964
  • Serrano-Munoz D, Avendano-Coy J, Simon-Martinez C, Taylor J, Gomez-Soriano J. 20-kHz alternating current stimulation: effects on motor and somatosensory thresholds. J Neuroeng Rehabil. 2020 Feb 19;17(1):22. doi: 10.1186/s12984-020-00661-x.

    PubMed 32075666
  • Serrano-Munoz D, Avendano-Coy J, Simon-Martinez C, Taylor J, Gomez-Soriano J. Effect of high-frequency alternating current transcutaneous stimulation over muscle strength: a controlled pilot study. J Neuroeng Rehabil. 2018 Nov 12;15(1):103. doi: 10.1186/s12984-018-0443-2.

    PubMed 30419966
  • Fernandez-Perez JJ, Serrano-Munoz D, Gomez-Soriano J, Alvarez DM, Avendano-Coy J. Selective nociceptive modulation using a novel prototype of transcutaneous kilohertz high-frequency alternating current stimulation: a crossover double-blind randomized sham-controlled trial. J Neuroeng Rehabil. 2024 Nov 15;21(1):203. doi: 10.1186/s12984-024-01503-w.

    PubMed 39548560

Questions about this trial

What is this clinical trial studying?

A study testing High-frequency alternating current stimulation in people with Healthy and Nerve Block, run by University of Castilla-La Mancha at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Juan Fernández-Pérez, PhD student (+34691336523, juanjose.fernandez@uclm.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pressure pain threshold (time frame: Baseline, during intervention at 10 minutes, post immediate at 15 minutes and 15 minutes post intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05230836, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in